Immunosuppressive drugs – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:14 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Immunosuppressive drugs – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Tacrolimus Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-tacrolimus-market-2021-2025/ Fri, 23 Apr 2021 13:03:00 +0000 https://www.cri-report.com/?post_type=product&p=11199 According to CRI’s market research, the sales value of Tacrolimus in China has an increasing trend from 2016 to 2020, with a CAGR of approximately 13.5% in 2016 to 2020. The sales revenue of Tacrolimus in China was CNY1.57 billion in 2020.

The post Investigation Report on China’s Tacrolimus Market 2021-2025 first appeared on CRI Report.

]]> Tacrolimus is a macrolide antibiotic and is also a new immunosuppressant. It is available in a variety of dosage forms. The ointment is used for moderate to severe atopic dermatitis where traditional therapies are not suitable, while the capsule and the injection are used to prevent graft rejection after liver or kidney transplantation. In recent years, Tacrolimus has become the first-line medication for liver and kidney transplantation. The Tacrolimus eye drop is used for vernal keratoconjunctivitis with poor anti-allergic treatment.
Tacrolimus’ original drug was developed by Fujisawa Pharmaceutical, which became Astellas after the merger. Tacrolimus was launched in China in 2005. In addition to Astellas, other manufacturers in the Chinese Tacrolimus market are Hangzhou Zhongmeihuadong, LEO, Zhejiang Hisun, and Sinopharm Chuankang.
According to CRI’s market research, the sales value of Tacrolimus in China has an increasing trend from 2016 to 2020, with a CAGR of approximately 13.5% in 2016 to 2020. The sales revenue of Tacrolimus in China was CNY1.57 billion in 2020. The growth rate in 2020 was 4.8% Year on Year, which slowed down compared to that in the previous years due to the COVID-19 epidemic.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Tacrolimus will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to market expansion. In light of research findings, the indication for preventing rejection in transplantation operations generates most sales for Tacrolimus. However, the number of new dialysis patients each year far exceeds the number of organ transplant operations, which means the demand for transplantation is not satisfied. With the development of policies and the increase in the number of organ donations, more patients will be able to receive transplants in the future, which will increase the demand for Tacrolimus.

Topics Covered:
-The impact of COVID-19 on China’s Tacrolimus market
– Sales value and volume of China’s Tacrolimus 2016-2020
– Competitive landscape of China’s Tacrolimus market
– Prices of Tacrolimus in China
– Prices of Tacrolimus in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Tacrolimus market
– Prospect of China’s Tacrolimus market from 2021 to 2025

The post Investigation Report on China’s Tacrolimus Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Lenalidomide Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-lenalidomide-market-2021-2025/ Fri, 23 Apr 2021 13:02:59 +0000 https://www.cri-report.com/?post_type=product&p=11193 According to CRI's market research, the sales revenue of Lenalidomide in the Chinese market has an increasing trend from 2016 to 2020. Especially after Lenalidomide was included in the national medical insurance catalog in the second half of 2017, the annual growth rate in 2018 reached 547.4%.

The post Investigation Report on China’s Lenalidomide Market 2021-2025 first appeared on CRI Report.

]]> Lenalidomide is an oral immunomodulatory drug that is mainly used to treat blood cancers such as multiple myeloma, myelodysplastic syndrome, and lymphoma. Lenalidomide was first developed by Celgene. Celgene’s Lenalidomide, REVLIMID was launched in China in 2013. In addition to Celgene, the other manufacturers in the Chinese Lenalidomide market are Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, and Beijing SL Pharmaceutical.

According to CRI’s market research, the sales revenue of Lenalidomide in the Chinese market has an increasing trend from 2016 to 2020. Especially after Lenalidomide was included in the national medical insurance catalog in the second half of 2017, the annual growth rate in 2018 reached 547.4%. In 2020, the annual growth rate slowed down due to the COVID-19 epidemic, which affected the overall hospital operation. The sales value of Lenalidomide was CNY297.4 million in 2020 and the CAGR of Lenalidomide from 2016 to 2020 is 98.7% in China.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Lenalidomide will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to price reduction and market expansion. In recent years, with the emergence of generic drugs, the price of Lenalidomide has kept decreasing, which increases the usage rate of Lenalidomide among Chinese patients. At the same time, Lenalidomide applied for its third indication in China in March 2021. As the number of approved indications increases in China, the sales will continue to grow.

Topics Covered:
-The impact of COVID-19 on China’s Lenalidomide market
– Sales value and volume of China’s Lenalidomide 2016-2020
– Competitive landscape of China’s Lenalidomide market
– Prices of Lenalidomide in China
– Prices of Lenalidomide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Lenalidomide market
– Prospect of China’s Lenalidomide market from 2021 to 2025

The post Investigation Report on China’s Lenalidomide Market 2021-2025 first appeared on CRI Report.

]]>